Tectonic Therapeutic, Inc. 8-K

What Happened

• Tectonic Therapeutic, Inc. (TECX) held its 2026 Annual Meeting of Stockholders on June 8, 2026 (record date April 13, 2026; 18,848,500 shares outstanding). Stockholders elected Timothy A. Springer and Stefan Vitorovic as Class II directors, ratified Deloitte & Touche LLP as the independent registered public accounting firm for 2026, and approved, on an advisory basis, the company’s executive compensation.
• On June 10, 2026 the company issued a press release announcing it completed enrollment in the TX45 APEX Phase 2 clinical trial in PH‑HFpEF patients (press release filed as Exhibit 99.1 to the Form 8‑K).

Key Details

• Shares outstanding at record date: 18,848,500.
• Director election votes:
  • Timothy A. Springer — For: 11,461,485; Withheld: 2,963,750; Broker non‑votes: 2,806,066.
  • Stefan Vitorovic — For: 13,937,996; Withheld: 487,239; Broker non‑votes: 2,806,066.
• Auditor ratification (Deloitte & Touche LLP): For 17,225,948; Against 3,831; Abstentions 1,522.
• Advisory vote on executive compensation: For 14,292,497; Against 118,271; Abstentions 14,467; Broker non‑votes 2,806,066.
• Press release date: June 10, 2026 — confirms completion of enrollment in TX45 APEX Phase 2 trial.

Why It Matters

• Governance: Election of directors and auditor ratification are routine governance outcomes that maintain board continuity and auditor oversight—important for investor confidence and ongoing reporting. The advisory approval of executive compensation indicates majority shareholder support for pay practices (non‑binding).
• Clinical milestone: Completing enrollment in the TX45 Phase 2 trial is a concrete development milestone for Tectonic’s clinical program in PH‑HFpEF patients. Enrollment completion typically enables the company to move to data readouts and next steps in the clinical timeline, which are potential near‑term catalysts for investors.